EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion

Nadja Ballin, Alexander Ott, Olga Seibel-Kelemen, Irina Bonzheim, Dominik Nann, Janina Beha, Stephan Spahn, Stephan Singer, Stephan Ossowski, Cristiana Roggia, Christopher Schroeder, Michael Bitzer und 1 weitere

Frontiers in Oncology · 07.04.2025 · 15

DOI: 10.3389/fonc.2025.1527484 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 07.04.2025. Verfasst von Nadja Ballin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FGFR2 fusions occur in up to 14% of patients with intrahepatic cholangiocarcinoma (iCCA) and have been considered as therapeutic target for FGFR inhibitors (FGFRi). However, response to targeted treatment may be limited due to the emergence of various resistance mechanisms. We report a case of recurrent iCCA in a 43-year-old patient with a FGFR2 fusion, who was treated with Lenvatinib. Next-generation sequencing (NGS) of tumor-normal DNA and tumor RNA under Lenvatinib treatment confirmed the FGFR2 fusion, however no further molecular resistance mutation was observed. After failure of FGFRi treatment (Lenvatinib and Infigratinib) ten months later, repeated NGS analysis revealed a new gain-of-function mutation in PIK3CA and a homozygous deletion of CDKN2A/B , potentially representing an acquired resistance mechanism. The emerging acquired resistance to FGFR inhibitor treatment has implications for subsequent treatment strategies.

Schlagwörter

Stichwörter der Autor:innen

CDKN2A/BFGFR inhibitionPIK3CAintrahepatic cholangiocarcinoma (iCCA)molecular tumor boardsecondary resistance

Autor:innen und Institutionen

  • Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.
  • Department of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.
  • Center for Personalized Medicine, University Hospital Tübingen, Tübingen, Germany.
  • Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.

Zitieren

APA

Ballin, N., Ott, A., Seibel-Kelemen, O., Bonzheim, I., Nann, D., Beha, J., Spahn, S., Singer, S., Ossowski, S., Roggia, C., Schroeder, C., Bitzer, M., & Armeanu-Ebinger, S. (2025). Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1527484

Vancouver

Ballin N, Ott A, Seibel-Kelemen O, Bonzheim I, Nann D, Beha J, et al. Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1527484

BibTeX
@article{Ballin2025,
  author = {Ballin, Nadja and Ott, Alexander and Seibel-Kelemen, Olga and Bonzheim, Irina and Nann, Dominik and Beha, Janina and Spahn, Stephan and Singer, Stephan and Ossowski, Stephan and Roggia, Cristiana and Schroeder, Christopher and Bitzer, Michael and Armeanu-Ebinger, Sorin},
  title = {Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1527484}
}
Kostenlos starten →